leisure time -WSS

leisure time

author：knowledge 2025-08-12 09:12:39 - browse：3

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Why palliative psychiatry is worth discussing

hotspot

Wikipedia

WSS

ASCO: Palliative care found as helpful given virtually as in person

Alabama frozen embryo ruling has major implications for IVF clinics

FDA's Pazdur wants cancer trials to range beyond China alone

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Cord blood banking comes at a high cost to babies

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

explore

leisure time

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

The cancer drug shortage isn’t new — and neither are the solutions

A solution to the after

Hepatitis C has a cure — but many Americans still lack access to it

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

After affirmative action ruling, medical educators look to 'holistic review'

NIH documents show early flaws of $1.6 billion long Covid program

knowledge

Cord blood banking comes at a high cost to babies

Antivenom research: Lessons from HIV applied in search for universal antidote

Community Health Systems hospitals under DOJ investigation

Ionis drug prevents swelling attacks due to hereditary angioedema

Shifting the focus from loneliness to social health

PBM reform efforts get punted in Congress

Wikipedia

hotspot

Wikipedia

hotspot